Member Info for Uncanny

Plus. just the starters from ME's hard work so hopefully multibag from here!

Lemon, stop being a Lemon and why would they sign a deal if no cash, maybe you're a lime?

There is nos stock!

Looked Level 2 and 3mn to sell at 0.6 and only 500K to buy at 0.75!

Says it all really

£16mn is an 8 bagger from here to start with unless ME drops another RNS!

Indeed and only valued at £2.25 mn - massive rerate to happen and the first finally completed legacy asset commercialised !!!!

Well done ME!

Just going to add that the cost savings we’re not reflected in the 2024 accounts 👍

Boston BIO

https://emea01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.linkedin.com%2Fposts%2Fvalirx-plc_bio2025-event-networking-activity-7338158008004198403-vGyU%3Futm_source%3Dshare%26utm_medium%3Dmember_ios%26rcm%3DACoAAA1LIgwBr8suZ6-q_42u9B82OT6Z-mDlizk&data=05%7C02%7C%7C5c855463cceb42cb72c108dda81a9e5b%7C84df9e7fe9f640afb435aaaaaaaaaaaa%7C1%7C0%7C638851554449126694%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=V6QBhbVeSvSSrcAcZP2ZHJP%2BVFvcT9yr3goxaYh%2BFU4%3D&reserved=0

Https://lnkd.in/eRkpWBYr

Shall we see what happens in the next 3 months and then you can comment?

Sorry

Don't be a D I C K Nom, playing on words.

Don't be D I C K Nom, playing on words.

Well said Patern!

Yes, I think those positive about the future like myself are loading up as I tried to buy a chunk yesterday but could only get 1.25mn shares all day. Tried again again today for a larger amount but all dried up up in any volume - so pressure forming on the SP like a pressure cooker!

Happy to move from 5% stake to over 6% .

We have a new kid on the block with 8% stake in the industry also in Mr Singh, who I guess is keeping quiet in the side-lines with all thy crxp on the BB's.

Completely forgot abut the looming results to be honest so perhaps a bit premature but back to where I bought yesterday as investors know value.

This means two things:

1. investors are mostly confident and happy about the prospects and if a placing does come at a higher level then they can sell out and buy back in if necessary or stick, but all appear happy to partake as the worm has changed as so much to look forward to.

2. what a mouth-watering line up of news we have potentially after the inevitable results, which were to be expected, albeit better than most anticipated with significant cost savings and a reduction in overall loss from last year!

So, place your bets guys and gals - top up, sell, buy fresh if you like what you see as you should hopefully all be over 18 and compos mentis!

For those lost too much sadly or diluted we are fed up with your constant whinging, so fxxx off and write off!

We are all fed up with the same negativity day in day out and buy a dog or a flower to make you happy as investing is not a charity and comes with risks or get a get well soon therapy as it won't reverse unless you sell out or partake in the placings to average done whilst we wait for good news and hopefully soon.

Live with it or get on with your life, but lease stop pouring the same negative drivel!

GLA, DYOR, NAI all IMHO

Also, Cathy is an immense asset to VAL with her as a fulltime director of research in positioning the assets who can best position the company to provide the company with the best science and optimal return of the science going forward.

Sadly, Adrian has left but lacked knowledge of the science and a good guy and great, but had no knowledge of the sector - how could he speak to a pharm or potential investor with out knowing the products?

As for Adam he moved to APTA as we know and again a great guy but went to a company that has fallen by the wayside and then a massive dilution raise so probably not best , so I am quite happy where we stand TBH

I think you forget that ME did actually say that he would take share option in lieu of salary say but its was shouted down at the AM which is full credit to him so he has his skin in the game and actually wanted more!

Nice to get some perspective on matters I think.

GLA IMHO NAI DYOR

No we have hit the US radars with the 70+ events ME has done over the last 7 months:

Take a look at Oric Pharma - 2 x phase 1b's and a Phase 2 asset and they just raised £125mn and have cash until end of 2026!

No, simply because buying on the dips, I can see an enormous upside in value here that has been well overlooked on the IP and too much focus on cash and the the results which are equally important of course (and the results were not a surprise and in fact encouraging), but as was mentioned bellow we went from 0.4p to 60p on the RNS of one IP RNS and we have 401 Ambrose, 201 / CLX SPV, Stingray, inflection points to reach on the IP which will hopefully multi-bag as we go from inception to developed drug status etc., plus many scorn the lab but this is a double whammy - provides income externally and growing, releasing much new IP and opportunism to follow through and provide massive costs savings for Val by bringing IP in house, in the recent fall in R'n'D for starters being !40k pa and I hope more to follow!

GLA, IMHO, NAI, DYOR

Also PM, don't forget about the potential £4.875,000 worth of warrant s that trigger too!

Livesushi, that is a standard going concern paragraph which appears with many results RNS’s

I actually thought under the circumstances they were good and certainly turning the corner and early days!

Grant funding in place for Dundee and CLX, hint that Stingray is to be progressed to be next SPV imho, big cost savings, ok increase in admin costs because of redundancies, but countered with £200k wage costs, healthy cash, £140k RnD saving by bringing assets in house through the lab and not outsourcing and loss reduced - all in 6 months with no legacy assets sold - TBC et al plus No key IP inflection point RNS’d yet I say well done ME and the ship is steadying nicely.

Extension of Dundee evaluation agreement with £50,000 grant from the Queen Mary University London Impact Fund.

· Grant funding secured to progress Cytolytix and Inaphaea programmes through Open University Knowledge transfer and Higher Education Innovation Fund schemes.

· Completion of Stingray evaluation agreement with negotiations underway for follow up underway post period.

· Termination of Barcelona and evaluation agreement.

· Initiation of strategic review to identify operational efficiencies and cost savings culminating in post period reductions of approximately £200, 000 in staffing costs.

· £49, 775 revenue from Inaphaea reflecting first payment of a multiphase contract and first sale of Assay ready reagents from Biobank bank.

Financial Highlights:

Research and developments costs of £245,163 for the year ended 31 December 2024 as compared to £383,362 in 2023, a reduction of £138,199 with cost savings due to reduced outsourced activities.

Administrative expenses of £1,976,283 for the year ended 31 December 2024 as compared to £1,886,401 in 2023, an increase of £89,882 reflecting increase staff costs and compensation paid and intellectual property costs.

Total comprehensive loss for the year ended 31 December 2024 of £1,915,693 as compared to £2,037,701 in 2023, and a loss per share of 1.45p as compared to 2.01p in 2023.

Cash balance at 31 December 2024 of £1,555,986 as compared to £174,684 in 2023.

Just for the record, l am not nervous LOL and quite comfortable here. GLA

Darth, when did you originally invest?